ALC
USDAlcon Inc. Ordinary Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$72.510
Kõrge
$74.005
Madal
$72.090
Maht
1.72M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
36.6B
Tööstusharu
Medical Instruments & Supplies
Riik
Switzerland
Kauplemisstatistika
Keskmine maht
2.25M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Seotud uudised
Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
Reminds STAAR's Board That It Does Not Need Alcon's Permission to Remain Independent or Run a Proper Strategic Alternatives Process Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
Alcon (SIX/NYSE:ALC), the global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR Surgical Company (NASDAQ:STAA) with the U.S. Securities and
Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
Questions Company's Adjournment and Postponement of the Special Meeting Without Substantive Explanation STAAR Should Heed the Strong Shareholder Opposition Already Expressed Through the Special Meeting Voting
Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
STAAR Should Not Delay the Inevitable and Should Let Shareholders Vote Company Should Not Commence a New "Go Shop" Period or Run a Rushed Sales Process Yunqi Capital Limited (together with its affiliates and the
Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
Appalled that STAAR's Board Reneged on Its Promise to Let Shareholders Decide the Fate of the Proposed Transaction in a Timely Manner Urges STAAR to Give Up on Misbegotten Transaction and Refocus on Running the
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced
Keybanc Maintains Overweight on Alcon, Lowers Price Target to $91
Keybanc analyst Brett Fishbin maintains Alcon with a Overweight and lowers the price target from $98 to $91.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.